Wu Shijin, Zhou Yuyang
School of Clinical Pharmacy (School of integrative Pharmacy), Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, 280 Waihuan East Road, Higher Education Mega Center, Panyu, Guangzhou, Guangdong 510006, China.
Ther Adv Psychopharmacol. 2024 Feb 6;14:20451253241227772. doi: 10.1177/20451253241227772. eCollection 2024.
Bipolar disorder (BD) is a severe mental disorder with various hypotheses regarding its pathogenesis. This article provides a summary of numerous studies on the variations in inflammatory cytokine levels in patients with BD and the effects of treatment with antipsychotics, mood stabilizers, and antidepressants on these levels. In addition, patients with autoimmune diseases who use anti-inflammatory monoclonal antibodies experience symptoms, such as depression, anxiety, and insomnia. These pieces of evidence suggest a potential association between immune inflammation and BD and offer new possibilities for therapy. Building upon this relationship, the authors propose an innovative approach for treating BD through individualized and precise therapy using anti-inflammatory monoclonal antibody drugs. To support this proposal, the authors compile information on pharmacological effects and relevant studies, including trials of various anti-inflammatory therapeutic monoclonal antibody drugs (e.g. infliximab, tocilizumab, and canakinumab) for the potential treatment of BD and its associated side effects in psychiatry. The authors categorize these anti-inflammatory monoclonal antibody drugs into levels I-IV through a comprehensive analysis of their advantages and disadvantages. Their potential is examined, and the need for further exploration of their pharmaceutical effects is established.
双相情感障碍（BD）是一种严重的精神障碍，关于其发病机制有多种假说。本文总结了众多关于BD患者炎症细胞因子水平变化以及抗精神病药物、心境稳定剂和抗抑郁药治疗对这些水平影响的研究。此外，使用抗炎单克隆抗体的自身免疫性疾病患者会出现抑郁、焦虑和失眠等症状。这些证据表明免疫炎症与BD之间存在潜在关联，并为治疗提供了新的可能性。基于这种关系，作者提出了一种通过使用抗炎单克隆抗体药物进行个体化精准治疗来治疗BD的创新方法。为支持这一建议，作者收集了药理作用及相关研究的信息，包括各种抗炎治疗性单克隆抗体药物（如英夫利昔单抗、托珠单抗和卡那单抗）用于BD潜在治疗及其在精神病学方面相关副作用的试验。作者通过对这些抗炎单克隆抗体药物的优缺点进行全面分析，将其分为I - IV级。研究了它们的潜力，并确定了进一步探索其药理作用的必要性。
